MedTrace Logo

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects

NCT02276430 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 939

Last updated 2025-09-15

No results posted yet for this study

Summary

Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late 1970s. Given the good prognosis of TC nowadays, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Current literature suggests that TC treatment, and specifically exposure to platinum agents, is associated with increased risk of cardiovascular morbidity and mortality. The precise role of treatment components like platinum in the pathogenesis of cardiometabolic changes and cardiovascular disease (CVD) warrants further investigation, since it is not known if CVD develops through direct platinum-induced damage of the vascular wall or by mediation through development of cardiometabolic riskfactors. The aim of this study is to identify risk factors for development for CVD after treatment for TC. A more profound insight into pathophysiologic mechanisms and identification of risk factors for CVDs is needed to facilitate development of preventive strategies and to optimize survivorship care.

Conditions

  • Testicular Cancer

Interventions

OTHER

Vena punction

Once 90 ml

Sponsors & Collaborators

  • The Netherlands Cancer Institute

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • J. A. Gietema, MD, PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-05-08
Completion
2026-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02276430 on ClinicalTrials.gov